Detalhe da pesquisa
1.
Ultrasound-based steatosis grading system using 2D-attenuation imaging: An individual patient data meta-analysis with external validation.
Hepatology
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38652643
2.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994647
3.
Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection.
J Viral Hepat
; 31(3): 137-142, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146596
4.
Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease.
Liver Int
; 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38558221
5.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37789669
6.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517286
7.
A comparative study of hepatic steatosis using two different qualitative ultrasound techniques measured based on magnetic resonance imaging-derived proton density fat fraction.
Hepatol Res
; 2024 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38294946
8.
Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study.
Hepatol Res
; 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38349813
9.
Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
Hepatol Res
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38685853
10.
Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease.
Hepatol Res
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38661715
11.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983642
12.
mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.
J Gastroenterol Hepatol
; 2024 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38403468
13.
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
J Gastroenterol Hepatol
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38602340
14.
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
J Gastroenterol Hepatol
; 39(5): 949-954, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38291715
15.
Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.
J Hepatol
; 2023 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37716372
16.
Multivariable Quantitative US Parameters for Assessing Hepatic Steatosis.
Radiology
; 309(1): e230341, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37787670
17.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552968
18.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455517
19.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37307798
20.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36657420